Barbara Krebs-Pohl, Ph.D
Administratrice indépendante
Dr. Barbara Krebs-Pohl holds a Ph.D. with a focus on antibody technologies and brings over 27 years of experience in biotechnology development, business strategy, and alliance creation. She most recently served as Chief Business Officer at MorphoSys, where she led the company’s acquisition by Novartis for USD 2.9 billion and played pivotal roles in the acquisition of Constellation Pharmaceuticals by MorphoSys and the USD 1.8 billion acquisition of HI-Bio by Biogen. Dr. Krebs-Pohl currently serves as Chair of the Board of Nykode Therapeutics ASA and OneChain Immunotherapeutics, as Managing Director of the Foundation for StemCell Research and Regenerative Medicine, and as Managing Director of Viopas Venture Consulting.